Previous 10 | Next 10 |
2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...
2024-02-21 08:15:02 ET JMP Securities analyst issues UNDERPERFORM recommendation for BCYC on February 21, 2024 08:00AM ET. The previous analyst recommendation was Underperform. BCYC was trading at $22.69 at issue of the analyst recommendation. The overall analyst consens...
2024-02-21 08:15:02 ET Needham analyst issues MARKET OUTPERFORM recommendation for BCYC on February 21, 2024 08:00AM ET. The previous analyst recommendation was Market Outperform. BCYC was trading at $22.69 at issue of the analyst recommendation. The overall analyst cons...
2024-02-20 09:22:48 ET More on Bicycle Therapeutics Circling Back On Bicycle Therapeutics Bicycle Therapeutics gains as former Seagen holder boosts stake Seeking Alpha’s Quant Rating on Bicycle Therapeutics Historical earnings data for Bicycle Therapeu...
Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer now active and recruiting patients BT8009 initial clinical data showed a promising ...
2024-02-13 06:57:52 ET More on Bicycle Therapeutics Circling Back On Bicycle Therapeutics Seeking Alpha’s Quant Rating on Bicycle Therapeutics Historical earnings data for Bicycle Therapeutics Financial information for Bicycle Therapeutics Re...
2024-02-07 17:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced that management will participate in a fireside chat at the Oppenheimer 34th A...
2024-01-28 00:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-22 18:18:15 ET Summary Today, we revisit Bicycle Therapeutics plc, a UK-based clinical stage biotech company focused on developing medicines for underserved diseases. The company has inked two significant collaboration deals with large drug makers in 2023 and continues to ...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
Multiple preclinical and clinical abstracts accepted for presentation at 2024 ASCO Annual Meeting and AACR Annual Meeting underscore breadth of Bicycle ® platform technology and pipeline Continued progress across research and development (R&D) pipeline, with numerous clinical...